Is Aster DM Health. overvalued or undervalued?

Nov 20 2025 08:08 AM IST
share
Share Via
As of November 19, 2025, Aster DM Health is considered overvalued with a high PE ratio of 91.71 and other elevated valuation metrics compared to its peers, despite a strong year-to-date stock return of 29.06%.
As of 19 November 2025, the valuation grade for Aster DM Health has moved from very expensive to expensive. The company is currently considered overvalued based on its high PE ratio of 91.71, a Price to Book Value of 7.58, and an EV to EBITDA of 41.94. These ratios significantly exceed those of its peers, such as Apollo Hospitals with a PE of 64.09 and EV to EBITDA of 33.69, indicating a substantial premium for Aster DM Health.

In comparison to its peers, Aster DM Health's PEG ratio stands at 0.00, which is notably lower than that of Narayana Hrudaya at 4.95, further emphasizing the overvaluation. Despite a strong year-to-date stock return of 29.06% compared to the Sensex's 9.02%, the elevated valuation ratios suggest that the stock may not sustain its current price levels in the long term.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News